Gland Pharma soars on executing strategic agreement with Global Pharmaceutical Company
Gland Pharma is currently trading at Rs. 2665.00, up by 64.55 points or 2.48% from its previous closing of Rs. 2600.45 on the BSE.
The scrip opened at Rs. 2639.60 and has touched a high and low of Rs. 2,675.15 and Rs. 2,632.50 respectively. So far 252 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2,675.15 on 10-Aug-2026 and a 52 week low of Rs. 1575.00 on 16-Mar-2026.
Last one week high and low of the scrip stood at Rs. 2,675.15 and Rs. 2491.35 respectively. The current market cap of the company is Rs. 42898.76 crore.
The promoters holding in the company stood at 51.77%, while Institutions and Non-Institutions held 39.18% and 9.05% respectively.
Gland Pharma has executed a strategic Manufacturing and Supply Agreement (MSA) with one of the leading global pharmaceutical companies for the technology transfer, manufacturing and supply of a portfolio of sterile injectable products for global markets. The partnership establishes Gland Pharma as an integrated end-to-end partner supporting multiple products across various stages of the product lifecycle, including both commercially marketed products and pipeline products under development. The collaboration follows a full-service CDMO model encompassing technology transfer, process development, scale-up, validation, commercial manufacturing, and long-term supply of sterile injectable products.
The portfolio comprises a diversified basket of oncology and non-oncology products in Vial, Lyo, Ampoules and pre-filled syringe (PFS) presentations, covering both complex and conventional injectable formulations. Under the agreement, Gland Pharma will leverage its integrated capabilities across development, technology transfer, manufacturing, quality and regulatory support to provide a comprehensive 'one-stop' solution to its partner.
The agreement is expected to provide strong long-term business visibility, with revenue generation anticipated from calendar year 2029. The current agreement covers 55 stock keeping units (SKUs) to be manufactured across three sites, with scope of adding more products soon. Once all products are commercialized, the annualized revenue potential is expected to be around $90-100 million. Technology transfer activities are planned for completion within two years, with revenues expected to commence from calendar year 2029.
